FUJIFILM Diosynth Biotechnologies Statement on COVID-19
2020-03-06
With employees, partners and operations across multiple geographies, FUJIFILM Diosynth Biotechnologies (“FDB”) is closely monitoring the evolving situation of COVID-19, along with the rest of the world.
The health of our employees and our partners is of utmost importance to us and we are taking precautions to minimize the spread of COVID-19 in alignment with government agency and WHO recommendations. FDB has established procedures to minimize disruption to our ongoing operations for the continued supply of both clinical and commercial manufactures.
To this end, FDB has currently suspended all business travel to countries and locations which are determined to be high risk of COVID-19 transmission. Additional controls and restrictions have been implemented for the access to our facilities. For additional information regarding a potential or planned visit, please contact your primary FDB representative or via the website.
Additional measures may be taken to protect our employees, partners and facilities as the COVID-19 situation evolves.
***